Lung cancer is the leading cause of cancer death and survival rates are poor. Non-small cell lung cancers (NSCLC), which account for 80% of lung cancers, comprise many different subtypes restricting treatment options.
Drugs that are more broadly effective are needed. 14-3-3 proteins are involved in the development of NSCLC and are a suitable target for drug development. We already have compounds that target 14-3-3 and will confirm NSCLC’s dependence on 14-3-3 and identify new drug candidates.